Zhitong Finance App News, Eling Pharmaceutical (002603.SZ) issued an announcement. Recently, the company received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration, and LB220-D08 sustained-release tablets were approved to conduct clinical trials on atypical hemolytic uremic syndrome (aHUS).

According to reports, LB220-D08 is a new small-molecule chemical drug independently developed by the company. It is a Class 1 new chemical drug with independent intellectual property rights. This product is a complement inhibitor targeting Factor B. By targeting and inhibiting factor B, this product can selectively inhibit the bypass pathway and block the activation of C3 convertase, thereby inhibiting the production of toxins such as C3a and C5a and the formation of C5 converting enzyme and membrane attack complexes (MAC, C5b-9), and maintaining the normal function of lectin and classical pathway signaling pathways.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.